A research team here at St. Jude, led by Howard Hughes Medical Investigator Brenda Schulman, PhD, have discovered a peptide that inhibits cullin neddylation, a process required for proper cell proliferation. It could be useful for drug screening and peptide screening applications; which could have therapeutic potential for treating cancer, inflammatory disorders and/or or pathogenic infections.
Peptide inhibitor, screening method, drug discovery, enzyme, cancer, pathogen, inflammation
Granted Patents or Published Applications
A patent application covering this peptide, its pharmaceutical use and screening methods for identifying additional inhibitors is currently pending.
Related Scientific References
The research underlying this discovery was reported last fall as Scott, D.C. et al., Science 334: 674-678 (Nov. 4, 2011).
We are currently seeking a corporate partner willing to commit their time and effort toward unlocking the therapeutic potential of this discovery. If you would like to learn more about this opportunity, please contact me at your earliest convenience.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.